argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$947.52−3.43 (-0.36%)
Close on Nov 17, 2026Market cap –P/E 48.4Yield –
argenx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $1.05B. The highest annual figure on record is $1.05B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | – |
| FY2024 | Dec 31, 2024 | -$21.65M | – |
| FY2023 | Dec 31, 2023 | -$425.05M | – |
| FY2022 | Dec 31, 2022 | -$720.34M | – |
| FY2021 | Dec 31, 2021 | -$348.75M | – |
| FY2020 | Dec 31, 2020 | -$477.62M | – |
| FY2019 | Dec 31, 2019 | -$198.89M | – |
| FY2018 | Dec 31, 2018 | -$81.85M | – |
See a number that looks wrong?